



30th March 2009

Company Announcements Office
Australian Securities Exchange

First Sales of Trophon EPR

Nanosonics Limited (ASX code: NAN) is pleased to announce that it has commenced production and commercial sale of its breakthrough Trophon™ EPR ultrasound probe disinfectant system, through distribution partners in New Zealand and Australia. Shipments, comprising Trophon EPR systems and NanoNebulant™ consumables, have been allocated to fulfil purchase orders already placed on the distribution partners by their customers, clinical end-users of the products.

The Company has undertaken a full sales launch to ultrasound professionals, including trade advertising and sales presentations to key opinion leaders and clinics throughout Australasia. Sales demand is being driven by the unique value proposition provided by the Trophon EPR system in the medical ultrasound market. A contributing factor to this demand is the greater awareness and vigilance of mandated legislation, regulatory requirements and the significant OH&S issues facing hospital and clinic staff.

The Trophon EPR is now being included in tenders submitted by the Original Equipment Manufacturers (OEMs). Further, the Company has been advised that the Trophon EPR has been incorporated as a condition in several new Government tenders, both in Australia and internationally.

Nanosonics has commenced a broad range of pre-launch activities in Europe, with first shipments expected in the next quarter of 2009. The Company has established a strong dealer network throughout Europe, each of whom has committed to commercial purchases of the Trophon EPR system to support the European launch.

It is expected that the Trophon EPR system will be launched in the near term into certain key markets in Asia, where the regulatory requirements for sale have already been met. Sales demand in this region is being influenced by the recent Guidelines issued by the US Centre for Disease Control (CDC), where the Trophon EPR system fully meets the requirements for routine high level disinfection of ultrasound probes between patients. Nanosonics is in advanced negotiations with leading distribution partners in the significant markets of North America and Japan.

The Trophon EPR system was submitted for an Australian international design award in February 2009 and has already been recognised as a finalist for this prestigious award. The award is recognised by the Australian Government and the International Council of Societies of Industrial Design, Australia's peak design assessment.



New Product Pipeline

Nanosonics now has substantial technical resources available to pursue additional commercial products based upon its novel NanoNebulant platform. Prototyping is now well advanced for several new devices which address substantial global market needs. The Company is in commercial discussions with both equipment manufacturers and other potential strategic partners, with a view to bringing devices to market where the Company's technology can deliver automated, safe, effective and environmentally sound solutions to the growing range of markets in healthcare and beyond.

David Radford Chief Executive

For more information please contact David Radford or Chris Grundy, Chief Financial Officer, on 61-2-8063 1600.

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

For more information about Nanosonics please visit www.nanosonics.com